Shambhu Aryal, MD
Pulmonary Disease · Falls Church, VANPI 1689841033
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Boehringer Ingelheim at 56.6% of the total. 2025 is the largest year on record at $15,061, more than ten times the $1,214 reported in 2019. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $137.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$27K
- ANI Pharmaceuticals, Inc.$6K
- United Therapeutics Corporation$5K
- Zambon USA Ltd.$4K
- Bayer$1K
- Xvivo Perfusion Inc.$934
- plus $4K from 31 others
Across 21 payments — averaging $3230.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$68K
What the payments were for
- Consulting fees$26,57355%
- Speaking & faculty fees$7,31015%
- Travel & lodging$4,5389%
- Food & beverage$9,70320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 51 | $27,234 |
| ANI Pharmaceuticals, Inc. | 19 | $5,583 |
| United Therapeutics Corporation | 95 | $5,253 |
| Zambon USA Ltd. | 2 | $3,560 |
| Bayer | 46 | $1,372 |
| Xvivo Perfusion Inc. | 2 | $934 |
| Actelion Pharmaceuticals US, Inc. | 13 | $500 |
| Insmed, Inc. | 24 | $469 |
| Transmedics, Inc. | 1 | $439 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $378 |
| Genentech USA, Inc. | 11 | $286 |
| AbbVie | 11 | $267 |
| Gilead | 13 | $243 |
| Astellas Pharma US Inc | 4 | $131 |
| Melinta Therapeutics, LLC | 7 | $126 |
| Pfizer | 1 | $123 |
| AstraZeneca | 1 | $115 |
| Vifor Pharma, Inc. | 2 | $113 |
| Kamada Ltd. | 1 | $110 |
| Merck | 4 | $104 |
| Sanofi | 1 | $102 |
| Paratek Pharmaceuticals, Inc. | 5 | $102 |
| Vertex | 4 | $92 |
| Sandoz | 3 | $72 |
| Mylan Specialty L.p. | 2 | $63 |
| La Jolla Pharmaceutical Company | 3 | $59 |
| Alcresta Therapeutics, Inc. | 2 | $59 |
| Shionogi Inc | 2 | $45 |
| Invivyd Inc | 2 | $31 |
| Inari Medical, Inc. | 1 | $26 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Abiomed | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| CMP Pharma, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$11,838
- PURIFIED CORTROPHIN GEL$4,941
- XVIVO Perfusion System (XPS)$934
- ORGAN CARE SYSTEM$439
- Adempas$400
- TYVASO$252
- ORENITRAM$252
- REMODULIN$252
- UPTRAVI$219
- OPSUMIT$219
- Esbriet$126
- ELIQUIS$123
- LIVTENCITY$120
- TEZSPIRE$115
- Cytogam$110
- DUPIXENT$102
How this compares
$48,123 in reported general payments places this provider in the 90th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 22 | $513,391 |
| OfevNintedanib Esylate | 35 | $457,499 |
| OpsumitMacitentan | 16 | $204,120 |
| Pirfenidone | 18 | $35,325 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $12,494 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,356 |
| Mycophenolate Mofetil | 32 | $2,189 |
| Tacrolimus | 19 | $1,602 |
| Tadalafil | 12 | $1,302 |
| MethotrexateMethotrexate Sodium | 12 | $556 |
| Prednisone | 72 | $553 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $305 |
| Spironolactone | 15 | $66 |
| Furosemide | 15 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $27,234 | $457,49935 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $500 | $204,12016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Falls Church
- Steven NathanFalls Church$1.5M
- Rabih HalabiFalls Church$604K
- Vikramjit KhangooraFalls Church$49K
- Anne BrownFalls Church$31K
- Omar MinaiHopewell$1.3M
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.